BNTC
NASDAQBenitec Biopharma Inc.
Website
News25/Ratings8
News · 26 weeks43-100%
2025-10-262026-04-19
Mix1190d
- Other5(45%)
- SEC Filings5(45%)
- Insider1(9%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by Benitec Biopharma Inc.10-K/A - Benitec Biopharma Inc. (0001808898) (Filer)
- PRBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l
- PRBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage th
- PRBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-dir
- PRBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- - An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to
- SECBenitec Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form 10-Q filed by Benitec Biopharma Inc.10-Q - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form EFFECT filed by Benitec Biopharma Inc.EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)
- SECSEC Form S-3 filed by Benitec Biopharma Inc.S-3 - Benitec Biopharma Inc. (0001808898) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
- INSIDERSEC Form 4 filed by Director Mates Sharon4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- PRBenitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301 HAYWARD, Calif., Jan. 11
- INSIDERDirector Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERDirector Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
- SECSEC Form SCHEDULE 13G filed by Benitec Biopharma Inc.SCHEDULE 13G - Benitec Biopharma Inc. (0001808898) (Subject)
- INSIDERSEC Form 4 filed by Benitec Biopharma Inc.4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Director Mehta Kishan4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Edward F4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Benitec Biopharma Inc.4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Benitec Biopharma Inc.4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- SECBenitec Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Benitec Biopharma Inc. (0001808898) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Mukadam Sophie4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Banks Jerel A.4 - Benitec Biopharma Inc. (0001808898) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Boston Megan4 - Benitec Biopharma Inc. (0001808898) (Issuer)